Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Lenalidomide + Obinutuzumab + RO7082859|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Obinutuzumab||Gazyva||R7159|afutuzumab|GA101|GA-101|RO 5072759||CD20 Antibody 17||Gazyva (obinutuzumab) is a glycoengineered anti-CD20 antibody that binds to CD20 on B-cells, resulting in increased antibody-dependent cellular cytotoxicity and induction of apoptosis, and potentially leading to decreased growth of B-cell tumors (PMID: 20194898, PMID: 21220500). Gazyva (obinutuzumab) is FDA approved in combination with Ambochlorin (chlorambucil) for chronic lymphocytic leukemia and in combination with Treanda (bendamustine) or chemotherapy for follicular lymphoma (FDA.gov).|
|RO7082859||Glofitamab|RO 7082859|RO-7082859||CD20 Antibody 17 CD3 Antibody 63||RO7082859 is a bispecific antibody that binds the tumor-associated antigen, MS4A1 (CD20), and CD3 on T-cells to stimulate T-cell killing of CD20-expressing tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04246086||Phase I||Tocilizumab Obinutuzumab Lenalidomide + Obinutuzumab + RO7082859 Lenalidomide + RO7082859 Lenalidomide + Mosunetuzumab||A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len) or Glofitamab + Len With or Without Obinutuzumab; and Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With R/R Follicular Lymphoma||Recruiting||USA | FRA | ESP||2|